Axiom is currently enrolling patients in Multiple Sclerosis, Alzheimer’s Disease, Essential Tremor and Migraine studies.
If you or a loved one would be interested in participating in a study for any of the listed fields, or if you would like more information on our studies, please contact us at email@example.com or
CURRENTLY ENROLLING STUDIES
1-A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
ClinicalTrials.gov Identifier: NCT04592874
2- New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning Study A Study to Improve Precision in Amyloid PET Coverage and Patient Care.
ClinicalTrials.gov Identifier: NCT04426539
3- A randomized double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE).
ClinicalTrials.gov Identifier: NCT04777396
4- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants with Mild Cognitive Impairment or Mild Dementia Due to Alzheimer’s Disease.
ClinicalTrials.gov Identifier: NCT05619692
1- A 2-year randomized, 3-arm, double-blind, non-inferiority study comparing the efficacy and safety of ofatumumab and siponimod versus fingolimod in pediatric patients with multiple sclerosis followed by an open-label extension.
ClinicalTrials.gov Identifier: NCT04926818
2- A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib
ClinicalTrials.gov Identifier: NCT05147220
A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson’s Disease.
ClinicalTrials.gov Identifier: NCT05424276